P1086REVERSE INCREMENTAL HEMODIALYSIS IS A GOOD METHOD FOR SETTING DIALYSIS DOSE CONSIDERING THE INDIVIDUAL RESIDUAL RENAL FUNCTION

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
TOSHIMASA TAKAHASHI ◽  
Yoshie Kanazawa ◽  
Toshiyuki Nakao

Abstract Background and Aims: We previously reported on Planned Incremental Hemodialysis (PIHD) for patients with good adherence to a prescribed diet and consideration of residual renal function (RRF), and some reports have been suggested that IHD in ESRD patients may have a positive effect on survival rates and RRF. On the other hand, the ESRD patients are commonly started on thrice-weekly HD at hospitals in Japan. However, and interestingly, careful observation of our ESRD patients whose CKD was gradually increased, and in some cases, we detected some recovery of their RRF. If there is RRF, IHD can be performed and potentially reduce dialysis frequency. We named this method “Reverse Incremental Hemodialysis (RIHD).” Method: One hundred thirteen patients who were started on thrice-weekly HD in other hospitals and who had been referred to our clinic since 2013, we selected 11 patients (9 males and two females) on the basis of their laboratory data and careful physical examination. The number of patients by the causes of their ESRD is as follows: 3 patients with Chronic glomerulonephritis, two patients with Nephrosclerosis, one patient with Diabetic kidney disease, one patient with Polycystic kidney disease, one patient with Chronic interstitial nephritis, one patient with Interstitial nephritis, one patient with Nephrotic syndrome, and one patient with Fabry disease. In order to reduce the number of dialysis sessions for patients, we considered the following laboratory data were required to be within the control standards before dialysis at the maximum dialysis interval, as follows: BUN<100mg/dL, serum creatinine<20.0 mg/dL, K<5.5mEq/L, HCO3->20.0mmol/L, respectively. To avoid over-volume, we also restricted the patient‘s weight gain as the Once-weekly HD patient is within 3.0 kg/week, and Twice-weekly HD patient is within 6.0 kg/week. We also checked physical examination and X-rays, if necessary, we sometimes checked the patient’s hANP. We also considered the dialysis volume evaluated like Peritoneal Dialysis (PD) such as weekly Kt/V urea above 1.7 together with RRF as an appropriate dialysis volume. Results: The average dialysis duration of 11 patients was 35.2 months (M) as 5-97M. Eight patients were able to reduce their HD from thrice-weekly to twice-weekly HD, and the average dialysis duration was 9.9M (1-32M). Three patients gradually reduced from thrice-weekly to once-weekly HD, and their average dialysis duration was 26.3M (10-37M). Eight patients who reduced their number of HD to twice-weekly HD, the average RRF weekly Kt/V urea was 0.10, actual HD weekly standardized (std) Kt/V urea was 1.37 and total weekly Kt/V urea was 1.47. Three patients who decreased their number of HD to once-weekly HD, the average RRF weekly Kt/V urea was 0.83, actual HD weekly std Kt/V urea was 0.56, and total weekly Kt/V urea was 1.39. Two patients (18.2%) had exceeded their weekly weight restriction, but no one had clinical symptoms of over-volume such as hypoxia, pulmonary edema, and pleural effusion. The laboratory data that we considered to be within the control standards before dialysis at the maximum dialysis interval was respected as 97.8% (11patients‘ BUN, s-Cr, K, and HCO3- laboratory datas:43 out of total 44 points) were observed. Their total weekly Kt/V urea data were lower than that of the weekly Kt/V urea recommended for PD patients, but our patient’s clinical status was within a controllable range. Conclusion: Some patients can gradually reduce the number of dialysis sessions with careful follow-up with considered their RRF and total weekly Kt/V urea, and setting weight gain limits individually. We still need to consider adjusting the treatment of total weekly Kt/V urea, as indicated by PD treatment recommendation for their prognosis. However, RIHD is a flexibly responds to insufficient renal function for RRT individually and might be suitable for QOL and cost-effective treatment for some ESRD patients.

2021 ◽  
Author(s):  
Anna Buckenmayer ◽  
Lotte Dahmen ◽  
Joachim Hoyer ◽  
Sahana Kamalanabhaiah ◽  
Christian S. Haas

Abstract Background: The erythrocyte sedimentation rate (ESR) is a simple laboratory diagnostic tool for estimating systemic inflammation. It remains unclear, if renal function affects ESR, thereby compromising its validity. This pilot study aims to compare prevalence and extent of ESR elevations in hospitalized patients with or without kidney disease. In addition, the impact of renal replacement therapy (RRT) modality on ESR was determined.Methods: In this single-center, retrospective study, patients were screened for ESR values. ESR was compared in patients with and without renal disease and/or RRT. In addition, ESR was correlated with other inflammatory markers, the extent of renal insufficiency and clinical characteristics.Results: A total of 203 patients was identified, showing an overall elevated ESR in the study population (mean 51.7±34.6 mm/h). ESR was significantly increased in all patients with severe infection, active vasculitis or cancer, respectively, independent from renal function. Interestingly, there was no difference in ESR between patients with and without kidney disease or those having received a prior renal transplant or being on hemodialysis. However, ESRD patients treated with peritoneal dialysis presented with a significantly higher ESR (78.3±33.1 mm/h, p<0.001), while correlation with other inflammatory markers was not persuasive.Conclusions: We showed that ESR: (1) does not differ between various stages of renal insufficiency; (2) may be helpful as a screening tool also in patients with renal insufficiency; and (3) is significantly increased in ESRD patients on peritoneal dialysis per se, while it seems not to be affected by hemodialysis or renal transplantation (see graphical abstract as supplementary material).


2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii539-iii539
Author(s):  
Hyung Jik Kim ◽  
Sung Gyun Kim ◽  
Jwa-Kyung Kim ◽  
Chan Ho Kim ◽  
Seung Jun Kim ◽  
...  

2020 ◽  
pp. 089686082097698
Author(s):  
Na Jiang ◽  
Chenhong Zhang ◽  
Hao Feng ◽  
Jiangzi Yuan ◽  
Li Ding ◽  
...  

Background: Gut microbiota alters in patients with end-stage renal disease, which contributes to inflammation, atherosclerosis, and results in increased incidence of cardiovascular diseases. The present study investigated the potential clinical factors, which influence the gut microbial structure and function in patients undergoing peritoneal dialysis (PD). Methods: This is a cross-sectional study performed in 81 prevalent PD patients. Gut microbiota was assessed by high throughput sequencing of 16S ribosomal ribonucleic acid gene in fecal samples. Gas chromatography was conducted to measure stool short-chain fat acid (SCFA) concentrations. Demographic parameters and clinical characteristics, including dialysis regimen, residual renal function, nutrition, and inflammation, were retrieved and related to the properties of gut microbiota. Results: PD duration, peritoneal glucose exposure, and estimated glomerulus filtration rate (eGFR) were identified to be associated with microbial variations. Significant separation of microbial composition was shown between patients with short or long PD duration ( p = 0.015) and marginal differences were found between patients grouped by different levels of peritoneal glucose exposure ( p = 0.056) or residual renal function ( p = 0.063). A couple of gut bacteria showed different abundance at amplicon sequencing variant level between these patient groups ( p < 0.05). In addition, stool isobutyric and isovaleric acid concentrations were significantly reduced in patients with longer dialysis duration, higher peritoneal glucose exposure, or declined eGFR ( p < 0.05). Conclusions: This pilot study demonstrated that long dialysis duration, high peritoneal glucose exposure, and loss of residual renal function were associated with gut microbiota alteration and reduced branched-chain SCFA production in PD patients.


1997 ◽  
Vol 82 (3) ◽  
pp. 847-850 ◽  
Author(s):  
Eddine Merabet ◽  
Samuel Dagogo-Jack ◽  
Daniel W. Coyne ◽  
Samuel Klein ◽  
Julio V. Santiago ◽  
...  

Abstract Leptin is a 16-kDa protein recently identified as the obese gene product involved in body weight regulation. Administration of recombinant leptin to ob/ob mice, which have a genetic defect in leptin production, reduces food intake and increases energy expenditure. Leptin is synthesized by fat cells, and in normal humans, plasma concentrations are proportional to adiposity. The physiological actions and the degradation pathways of leptin in humans are unknown. We investigated renal elimination of leptin by comparing plasma leptin concentrations in end-stage renal disease (ESRD) patients with normal controls. Our hypothesis was that if renal filtration is a significant route of elimination, the hormone would accumulate in ESRD patients. Mean plasma levels in 141 ESRD patients (26.8 ± 5.7 and 38.3 ± 5.6 μg/L for males and females, respectively) were significantly higher (P&lt; 0.001) than mean values obtained in normal controls (11.9 ± 3.1 and 21.2 ± 3.0 μg/L for males and females, respectively). Leptin concentrations in ESRD patients correlated directly with body mass index (BMI; r = 0.77 for men and 0.78 for women). The rate of increase in leptin concentrations with BMI was significantly greater in ESRD patients (5.5 and 6.6 μg/L/U BMI for men and women, respectively) than in normal controls (1.4 and 2.6 μg/L/U for men and women, respectively). Pre- and postdialysis leptin levels in hemodialysis patients were similar. Western blot of plasma from ESRD patients with high leptin levels showed bands corresponding to the intact protein (16 kDa) with no lesser or greater molecular mass species observed. Leptin concentrations in patients with ESRD did not correlate with measures of residual renal function (serum creatinine,β 2-microglobulin, PTH, or GH levels). Similarly, we found no correlation between leptin levels and the number of years patients had been on dialysis or with recent weight changes. We conclude that intact leptin is increased in ESRD patients, but does not appear to cause decreased weight. As leptin levels did not correlate with residual renal function, increased production may account for the high levels observed.


2020 ◽  
Vol 10 (1) ◽  
pp. 10-20
Author(s):  
A. I. Dyadyk ◽  
G. G. Taradin ◽  
Yu. V. Suliman ◽  
S. R. Zborovskyy ◽  
V. I. Merkuriev

The issues of diuretic therapy in patients with chronic kidney disease, pharmacokinetics of diuretics, the problem of diuretic resistance, the tactics of using thiazides and loop diuretics in patients with various stages of chronic kidney disease, according to the recommendations of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative are discussed in the article. Particular attention is paid to the prescription of this group of drugs to patients with end stage renal disease, as well as those undergoing renal replacement therapy (hemodialysis).Diuretics play an important role in the management of patients with chronic kidney disease with the development of hypertension and an increased extracellular fluid volume. In case of impaired renal function leading place is given to loop diuretics. Their combination with thiazide diuretics can increase the diuretic effect. The results of clinical trials assessing the effectiveness of the use of diuretics during decline of residual renal function are provided. It is reported about the effect of potassium-sparing diuretics on the incidence of cardiovascular complications, the development of hyperkalemia in patients undergoing dialysis treatment. The importance of continuation of intensive study about the possibility of antagonists of mineralocorticoid receptors usage, in particular the spironolactone, eplerenone, and finerenone in order to reduce cardiovascular complications and mortality, is indicated.


Sign in / Sign up

Export Citation Format

Share Document